Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accumulated Expenses: 2023-2024

Historic Accumulated Expenses for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $14.7 million.

  • CG Oncology's Accumulated Expenses rose 80.27% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 80.27%. This contributed to the annual value of $14.7 million for FY2024, which is 40.43% up from last year.
  • According to the latest figures from FY2024, CG Oncology's Accumulated Expenses is $14.7 million, which was up 40.43% from $10.4 million recorded in FY2023.
  • CG Oncology's 5-year Accumulated Expenses high stood at $14.7 million for FY2024, and its period low was $10.4 million during FY2023.
  • Its 2-year average for Accumulated Expenses is $12.6 million, with a median of $12.6 million in 2023.
  • Data for CG Oncology's Accumulated Expenses shows a peak YoY skyrocketed of 40.43% (in 2024) over the last 5 years.
  • CG Oncology's Accumulated Expenses (Yearly) stood at $10.4 million in 2023, then surged by 40.43% to $14.7 million in 2024.